These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23370249)

  • 1. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective.
    Maliepaard M; Nofziger C; Papaluca M; Zineh I; Uyama Y; Prasad K; Grimstein C; Pacanowski M; Ehmann F; Dossena S; Paulmichl M
    Nat Rev Drug Discov; 2013 Feb; 12(2):103-15. PubMed ID: 23370249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives.
    Prasad K; Breckenridge A
    Drug Discov Today; 2011 Oct; 16(19-20):867-72. PubMed ID: 21920454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments.
    Otsubo Y; Ishiguro A; Uyama Y
    Pharmacogenomics; 2013 Jan; 14(2):195-203. PubMed ID: 23327579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory watch: FDA guidance on co-developing investigational drugs.
    Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulatory approval for new pharmacogenomic tests: a comparative overview.
    Joly Y; Koutrikas G; Tassé AM; Issa A; Carleton B; Hayden M; Rieder MJ; Ramos-Paque E; Avard D
    Food Drug Law J; 2011; 66(1):1-24, i. PubMed ID: 24505844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development.
    Vicini P; Fields O; Lai E; Litwack ED; Martin AM; Morgan TM; Pacanowski MA; Papaluca M; Perez OD; Ringel MS; Robson M; Sakul H; Vockley J; Zaks T; Dolsten M; Søgaard M
    Clin Pharmacol Ther; 2016 Feb; 99(2):198-207. PubMed ID: 26536838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
    Lesko LJ; Woodcock J
    Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia.
    Noguchi A; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2022 May; 56(3):523-529. PubMed ID: 35181842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts.
    Nelson B
    Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetics and public policy: expert views in Europe and North America.
    Melzer D; Detmer D; Zimmern R
    Pharmacogenomics; 2003 Nov; 4(6):689-91. PubMed ID: 14596633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2013 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
    [No Abstract]   [Full Text] [Related]  

  • 12. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):701. PubMed ID: 24073621
    [No Abstract]   [Full Text] [Related]  

  • 13. The integration and interpretation of pharmacogenomics - a comparative study between the United States of America and Europe: towards better health care.
    Bartlett MJ; Shephard EA
    Drug Metab Pers Ther; 2016 Jun; 31(2):91-6. PubMed ID: 27269898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan.
    Ishiguro A; Yagi S; Uyama Y
    J Hum Genet; 2013 Jun; 58(6):313-6. PubMed ID: 23657427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
    Avery M
    Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
    Roberts SA; Allen JD; Sigal EV
    Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
    Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
    Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current PMDA Activities for Use of Biomarkers in Drug Evaluation].
    Ishiguro A
    Yakugaku Zasshi; 2015; 135(5):681-4. PubMed ID: 25948301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoliberal technocracy: explaining how and why the US Food and Drug Administration has championed pharmacogenomics.
    Hogarth S
    Soc Sci Med; 2015 Apr; 131():255-62. PubMed ID: 25661300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics in drug regulation: promise, potential and pitfalls.
    Shah RR
    Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1617-38. PubMed ID: 16096112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.